Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.

MLA

Korjian, Serge, et al. “Safety and Efficacy of Rivaroxaban for the Secondary Prevention Following Acute Coronary Syndromes among Biomarker-Positive Patients: Insights from the ATLAS ACS 2-TIMI 51 Trial.” European Heart Journal. Acute Cardiovascular Care, vol. 8, no. 2, Mar. 2019, pp. 186–93. EBSCOhost, https://doi.org/10.1177/2048872617745003.

APA

Korjian, S., Braunwald, E., Daaboul, Y., Verheugt, F., Bode, C., Tendera, M., Jain, P., Plotnikov, A., Burton, P., & Gibson, C. M. (2019). Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. European Heart Journal. Acute Cardiovascular Care, 8(2), 186–193. https://doi.org/10.1177/2048872617745003

Chicago

Korjian, Serge, Eugene Braunwald, Yazan Daaboul, Freek Verheugt, Christoph Bode, Michal Tendera, Purva Jain, Alexei Plotnikov, Paul Burton, and C Michael Gibson. 2019. “Safety and Efficacy of Rivaroxaban for the Secondary Prevention Following Acute Coronary Syndromes among Biomarker-Positive Patients: Insights from the ATLAS ACS 2-TIMI 51 Trial.” European Heart Journal. Acute Cardiovascular Care 8 (2): 186–93. doi:10.1177/2048872617745003.